Loading...
http://jcps.bjmu.edu.cn

Table of Content

    04 November 2023, Volume 32 Issue 10
    Review
    Sialic acid-functionalized targeted drug delivery systems: advances in tumor and inflammation therapy by binding to Siglecs or selectin receptors
    Kai Li, Bingjie Tang, Xinlong Chai, Yang Ping, Lihong Wang, Jin Su
    2023, 32(10):  773-795.  DOI: 10.5246/jcps.2023.10.064
    Asbtract ( 140 )   HTML ( 27)   PDF (8275KB) ( 34 )  
    Figures and Tables | References | Related Articles | Metrics

    Targeted drug delivery systems are highly desirable for their ability to release drugs specifically at targeted sites. Among these systems, active targeting is considered the most promising. However, the nanomaterials commonly used for constructing the targeting moiety of multifunctional drug delivery vehicles have several disadvantages that limit their applications, such as low biocompatibility, susceptibility to elimination by the mononuclear phagocyte system, and difficulty in modification. Sialic acid, a natural ligand, is often present as the terminal sugar of glycans on glycoproteins or glycolipids on the cell surface. As an endogenous substance, it is highly biocompatible, has a clear molecular structure, and is easy to chemically modify. Sialic acid-functionalized nanoparticles can carry drugs that target cells expressing receptors (sialic acid-binding immunoglobulin-like lectin or selectin receptors) for the treatment of diseases. In the present review, we presented current literature on sialic acid-decorated nanoparticle-based targeted drug delivery systems that bind to “sialic acid-binding immunoglobulin-like lectin or selectin receptors” for therapeutic effects in tumors or inflammation. We also discussed chemical modification strategies for natural sialic acid ligands to improve binding affinity and selectivity to receptors.

    Original articles
    Unraveling the biological and immunological mechanisms of safflower-danshen in the treatment of coronary atherosclerotic heart disease: a comprehensive bioinformatics and single-cell sequencing approach
    Dongsheng Wei, Xiaosheng Liu, Luzhen Li, Jiajie Qi, Yuxuan Wang, Zhe Zhang
    2023, 32(10):  796-812.  DOI: 10.5246/jcps.2023.10.065
    Asbtract ( 107 )   HTML ( 16)   PDF (22599KB) ( 37 )  
    Figures and Tables | References | Related Articles | Metrics

    In the present study, we investigated the mechanism of safflower-danshen treatment for coronary artery disease (CAD) through bioinformatics, network pharmacology, and single-cell sequencing. To identify target genes for hydroxy safflower yellow pigment, tanshinone, danshinolic acid, and tanshinol, we employed various databases, including Comparative Toxicogenomics Database, Swiss target prediction, Binding Database Home, and TargetNet. By analyzing three CAD datasets obtained from the GEO database, we identified CAD-associated genes using differential analysis and a weighted gene coexpression network analysis (WGCNA). We integrated drug-disease genes and utilized the mcode plugin in Cytoscape to identify core subgroups in the drug-disease regulatory networks. The infiltration of 38 immune cells/functions was assessed using the ssGSEA algorithm. Additionally, single-cell RNA sequencing (SCS) was employed to examine the distribution of cellular subpopulations within the mcode regulatory network. Finally, we performed GO and KEGG enrichment analyses for drug target genes, disease genes, and mcode core subpopulation genes. Our results revealed 485 drug target genes obtained from four databases. Through differential analysis and WGCNA, we identified 617 disease genes associated with CAD. The mcode plugin analysis yielded a drug-disease core regulatory subpopulation consisting of 99 genes. The ssGSEA algorithm indicated that members of the TGFβ family, chemokines, and interleukin receptors might play key roles in the immune regulation of safflower-danshen treatment for CAD. Furthermore, SCS results suggested that macrophages and monocytes might be core cell subpopulations within this context. GO and KEGG enrichment analyses highlighted endosome-bound organelles and nuclei as potentially important cellular components. In conclusion, safflower-danshen treatment for CAD might exert its therapeutic effects by modulating TGFβ family members, chemokines, interleukin receptors, macrophages, monocytes, endosome-bound organelles, and nuclei.

    Exploring the landscape of stem cell research for Alzheimer's disease: A bibliometric analysis spanning 2002–2021
    Fangcun Li, Ding Zhang, Zi Li, Zhaomeng Hou, Wei Chen, Jie Chen, Yueqiang Hu
    2023, 32(10):  813-834.  DOI: 10.5246/jcps.2023.10.066
    Asbtract ( 56 )   HTML ( 9)   PDF (6538KB) ( 35 )  
    Figures and Tables | References | Related Articles | Metrics

    An increasing number of research on stem cells and Alzheimer's disease (AD) has been accomplished, making stem cells the research hotspot in the field. This study was conducted to identify the hotspots and trends of research related to stem cells and AD through a bibliometric analysis. A systematic search was performed in the Web of Science Core Collection database for relevant articles published from 2002 to 2021. Data were analyzed through Cite Space and VOS viewer. Stem cell research into AD covered 94 countries/regions, with a total of 3629 institutions participating, and showed an increasing trend every year, with the United States and China being the major countries studied. Takahashi’s team cultured the induced pluripotent stem cells for the first time, which became the source of many researchers’ theories. The University of California System is the organization with the most impact on research results. Plos One is the most popular journal. Maiese found that SIRT1 is the treatment target of AD, and his research results are the most. Research interests include brain, dentate gyrus, amyloid-beta, oxidative stress, neurodegeneration, inflammation, pluripotent stem cells, neutralistic stem cells, and microglia. Our study revealed the global research trend of stem cells in AD. At present, the research hotspot is the research of induced pluripotent stem cell models in AD. It provides important information and reference for researchers in this field.

    Analysis of adverse drug reactions caused by carbapenems and review of related literature
    Xinyu Chang, Lijuan Han, Yang Liu, Zheng Fan, Jiankun Wu
    2023, 32(10):  835-841.  DOI: 10.5246/jcps.2023.10.067
    Asbtract ( 63 )   HTML ( 2)   PDF (1396KB) ( 19 )  
    Figures and Tables | References | Related Articles | Metrics

    This study aimed to review the literature on adverse drug reactions (ADRs) caused by the clinical use of carbapenems and their effects on platelet abnormalities. We also analyzed the clinical characteristics of these cases and provided references for the safe clinical use of carbapenems. Individual cases of platelet abnormalities caused by the carbapenem drugs, including imipenem and meropenem, were collected from PubMed, Medline, the Chinese Academic Journal Full-text Database (CNKI), and the Vip Chinese Science and Technology Journal Database. The patients’ conditions (such as sex and age), diseases, and prognoses were statistically analyzed. Three cases of platelet abnormalities were observed after the clinical use of imipenem, and 17 cases were reviewed for meropenem. Among these cases, carbapenem caused 11 cases of platelet elevation and 9 cases of thrombocytopenia. The ADRs were resolved within 4–18 d after drug withdrawal and were classified as serious adverse drug reactions. Although there are limited reports of ADRs caused by carbapenems resulting in platelet abnormalities, the consequences can be serious. Therefore, in clinical practice, special attention should be given to the ADRs of carbapenems in blood, early monitoring, and timely symptomatic treatment.

    Drug administration and clinical pharmacy column
    Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China
    Jun Ma, Liangyu Ni, Qiyun Zhu, Zhao Yang, Bin Jiang
    2023, 32(10):  842-851.  DOI: 10.5246/jcps.2023.10.068
    Asbtract ( 97 )   HTML ( 6)   PDF (2401KB) ( 21 )  
    Figures and Tables | References | Related Articles | Metrics

    Siltuximab is an innovative drug used to treat idiopathic multicentric Castleman disease (iMCD), a rare condition. Clinical trials have demonstrated its efficacy and safety. However, there is limited research on the economic evaluation of siltuximab. Therefore, using a partition survival model, we aimed to evaluate the average treatment cost and health outcomes for Chinese patients with iMCD in the siltuximab group compared to the placebo group based on existing clinical and published data. We also conducted price threshold analysis, incremental cost-utility analysis, and sensitivity analysis. The results revealed that compared to the placebo group, the siltuximab group showed an increase of 6.31 life-years (LYs) and 5.09 quality-adjusted life-years (QALYs). At a willingness-to-pay (WTP) threshold of 242 928 yuan/QALY, the maximum price threshold for siltuximab compared to the placebo group was 8921.47 yuan per bottle (400 mg). Therefore, as a first-line treatment for iMCD, siltuximab demonstrated superior health outcomes compared to placebo.

    Efficacy and safety of venous thromboembolism prevention in lung cancer: a meta-analysis of randomized controlled studies
    Limei Su, Xiyue Mao, Limei Yang
    2023, 32(10):  852-860.  DOI: 10.5246/jcps.2023.10.069
    Asbtract ( 90 )   HTML ( 4)   PDF (2796KB) ( 24 )  
    Figures and Tables | References | Related Articles | Metrics

    Venous thromboembolism (VTE) is a significant complication and a risk factor for mortality in patients with lung tumors. Anticoagulation therapy plays a crucial role in the prevention of VTE. However, its safety and effectiveness, specifically in lung cancer patients, have not been systematically evaluated. This study aimed to conduct a meta-analysis to assess the efficacy and safety of prophylactic anticoagulation in patients with lung cancer. We systematically searched for relevant literature published in Pubmed, Embase, CNKI, and Wanfang databases until September 2020 and screened the literature according to predefined inclusion and exclusion criteria. The included studies were evaluated for quality using the modified Jadad scale, and Review Manager 5.4 software was used for data analysis. Four randomized controlled trials (n = 2272 participants) were included in the meta-analysis. The quality evaluation revealed that two articles were of high quality (≥ 4 points), while the remaining articles were of low quality (≤ 3 points). The average Jadad score for all references was 3.5. The meta-analyses demonstrated that anticoagulant therapy significantly reduced the incidence of VTE in lung cancer patients [RR = 0.55, 95% CI (0.43, 0.70), P < 0.00001]. However, there were no statistically significant differences in the incidence of total bleeding [RR = 1.74, 95% CI (0.87, 3.50), P = 0.12], minor bleeding [RR = 1.64, 95% CI (0.66, 4.05), P = 0.29], and major bleeding [RR = 1.70, 95% CI (0.91, 3.16), P = 0.10]. In conclusion, anticoagulant therapy effectively reduced the incidence of VTE in lung cancer patients without a statistically significant increase in bleeding complications.

    News
    The team of Prof. Ning Jiao and the teams of Prof. Xiao Yu and Prof. Jinpeng Sun have made important progress in the discovery and treatment of new targets for diabetes
    State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center
    2023, 32(10):  861-862. 
    Asbtract ( 43 )   PDF (1918KB) ( 14 )  
    Related Articles | Metrics
    The team of Prof. Ning Jiao and the teams of Prof. Xiao Yu and Prof. Jinpeng Sun have made important progress in the discovery and treatment of new targets for diabetes.
    The team of Prof. Min Ye and Prof. Xue Qiao have made new progress in the catalytic mechanism and rational transformation of regiospecific saponin acetyltransferase from Astragalus membranaceus
    State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center
    2023, 32(10):  863-864. 
    Asbtract ( 54 )   PDF (1751KB) ( 5 )  
    Related Articles | Metrics
    The team of Prof. Min Ye and Prof. Xue Qiao have made new progress in the catalytic mechanism and rational transformation of regiospecific saponin acetyltransferase from Astragalus membranaceus.